Catalyst Repository | NantKwest Inc. Common Stock

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia 15 Apr 2025 08:41:32

https://immunitybio.com/immunitybio-announces-fda-submissions-of-supplemental-bla-for-nmibc-papillary-disease-and-for-expanded-access-of-anktiva-to-treat-lymphopenia/

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch 07 Apr 2025 07:56:47

https://immunitybio.com/immunitybio-to-host-key-opinion-leader-and-investor-meeting-to-provide-updates-on-clinical-programs-and-anktiva-commercial-launch/

ImmunityBio to Host Investor Day 26 Mar 2025 10:42:16

https://immunitybio.com/immunitybio-to-host-investor-day/

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites in the Process of Launching 13 Mar 2025 10:11:27

https://immunitybio.com/immunitybio-announces-first-dosing-of-recombinant-bcg-rbcg-in-the-u-s-and-60-sites-in-the-process-of-launching/

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 03 Mar 2025 08:12:35

https://immunitybio.com/immunitybio-reports-sales-momentum-unit-growth-since-permanent-j-code-issuance-j9028-in-january-2025-and-financial-results-for-year-end-2024/

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage 19 Feb 2025 09:13:22

https://immunitybio.com/fda-authorizes-immunitybio-to-provide-recombinant-bcg-rbcg-to-urologists-to-address-tice-bcg-shortage/

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ 13 Feb 2025 15:42:43

https://immunitybio.com/immunitybio-announces-uk-medicines-and-healthcare-products-regulatory-agency-accepted-marketing-authorization-application-for-anktiva-for-the-treatment-of-patients-with-bcg-unresponsive-non-musc/

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer 29 Jan 2025 08:56:11

https://immunitybio.com/immunitybio-announces-collaboration-with-beigene-on-confirmatory-phase-3-trial-of-anktiva-and-pd-1-checkpoint-inhibitor-combination-in-non-small-cell-lung-cancer/

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ 27 Jan 2025 10:57:10

https://immunitybio.com/immunitybio-announces-european-medicines-agency-acceptance-of-marketing-authorization-application-for-anktiva-for-the-treatment-of-patients-with-bcg-unresponsive-non-muscle-invasive-bladder-canc/

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency 15 Jan 2025 17:56:32

https://immunitybio.com/immunitybio-provides-regulatory-update-on-anticipated-fda-submissions-in-2025-following-meeting-with-the-agency/

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® is Now Effective 06 Jan 2025 09:27:23

https://immunitybio.com/immunitybio-announces-permanent-j-code-j9028-for-anktiva-is-now-effective/

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months 19 Nov 2024 08:59:49

https://immunitybio.com/immunitybio-completes-anktivas-post-approval-enrollment-of-the-100th-patient-in-bcg-unresponsive-nmibc-cis-trial-and-reports-a-complete-response-rate-of-71-with-a-durable-duration-of-response/

ImmunityBio Reports Third-Quarter 2024 Financial Results 12 Nov 2024 10:29:57

https://immunitybio.com/immunitybio-reports-third-quarter-2024-financial-results/

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma 24 Oct 2024 09:30:24

https://immunitybio.com/first-patients-dosed-in-phase-1-clinical-study-of-immunitybios-car-nk-cell-therapy-for-the-treatment-of-relapsed-b-cell-non-hodgkin-lymphoma/

ImmunityBio to Participate in the Jefferies London Healthcare Conference 21 Oct 2024 09:30:27

https://immunitybio.com/immunitybio-to-participate-in-the-jefferies-london-healthcare-conference-2/

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer 09 Sep 2024 08:33:18

https://immunitybio.com/immunitybio-presents-positive-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy/

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval 12 Aug 2024 09:00:45

https://immunitybio.com/immunitybios-anktiva-now-covered-by-more-than-a-dozen-insurance-plans-representing-over-100-million-lives-within-months-of-fda-approval/

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer 06 Aug 2024 09:31:09

https://immunitybio.com/immunitybio-announces-study-of-anktiva-in-combination-with-the-adher2dc-cancer-vaccine-as-a-potential-therapy-to-control-endometrial-cancer/

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors 20 Jun 2024 09:30:52

https://immunitybio.com/immunitybio-announces-insurance-coverage-of-anktiva-across-multiple-states-with-first-commercial-doses-administered-just-weeks-after-fda-approval-opening-new-era-for-immunotherapy-beyond/

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast 17 May 2024 09:15:48

https://immunitybio.com/connecting-the-dots-of-anktivas-triangle-offense-a-deep-dive-with-dr-patrick-soon-shiong-and-dr-ashish-kamat-in-a-three-part-urotoday-podcast/

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA® 07 May 2024 08:16:31

https://immunitybio.com/immunitybio-completes-gmp-drug-substance-manufacturing-sufficient-for-170000-doses-of-anktiva/

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types 02 May 2024 16:16:08

https://immunitybio.com/immunitybio-serum-institute-of-india-agree-on-an-exclusive-arrangement-for-global-supply-of-bacillus-calmette-guerin-bcg-across-all-cancer-types/

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association 30 Apr 2024 08:46:06

https://immunitybio.com/immunitybio-executive-chairman-dr-patrick-soon-shiong-to-discuss-anktiva-approval-in-fireside-chat-at-the-annual-conference-of-the-american-urological-association/

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy 06 Mar 2024 09:16:23

https://immunitybio.com/niaid-sponsored-study-shows-n-803-combined-with-neutralizing-antibodies-could-lead-to-sustained-hiv-viral-control-after-discontinuation-of-antiretroviral-therapy/

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study 05 Mar 2024 09:31:24

https://immunitybio.com/n-803-combined-with-natural-killer-cells-showed-potential-to-reduce-hiv-viral-load-in-hiv-positive-subjects-part-of-hiv-cure-study/

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial 21 Feb 2024 10:01:22

https://immunitybio.com/immunitybio-announces-full-accrual-of-first-two-phases-of-cancer-vaccine-trial-in-participants-with-lynch-syndrome-and-initiation-of-randomized-controlled-phase-of-the-trial/

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG 05 Feb 2024 09:31:32

https://immunitybio.com/immunitybio-quality-of-life-study-in-bcg-unresponsive-bladder-cancer-trial-indicates-improved-physical-function-in-the-71-complete-responders-suggesting-a-favorable-risk-benefit-ratio-for-n-803-plus-b/

NantKwest Inc. Common Stock

NK Overview

Latest News